Gaugene

About Gaugene

Gaugene, operating under the name Beijing Zhizhen Biotechnology Co., Ltd., is a high-tech company established in 2017 with its headquarters in Beijing, China. The enterprise was jointly founded by individuals described as core technology management backbones from well-known domestic in-vitro diagnostic (IVD) companies, bringing a wealth of management experience to the venture. Gaugene has successfully secured $19.6M in funding from investors including Daoyuan Capital, Fortune Capital, and Guangdong Hybribio Biotech Company.

The firm specializes in the development and supply of advanced hematology testing instruments and reagents for the in-vitro diagnostic market. Its client base consists of in-vitro diagnostic users who utilize the company's products for hematology diagnosis, other clinical diagnoses, and life science research. The business model centers on the research, development, manufacturing, and sale of these specialized medical diagnostic tools and consumables. Gaugene operates in the diagnostic equipment industry, a competitive space where it is one of 19 identified competitors.

Gaugene's product portfolio is distinguished by its use of high-power flow lasers and high-sensitivity multi-color fluorescence detection systems, a feature it reports as unique in China. This technology provides solutions for clinical diagnosis and supports flow cytometry technology applications in single-cell research, protein screening, and the discovery of new clinical indicators. By developing and providing these sophisticated instruments and reagents, the company aims to deliver advanced and reliable solutions to the life sciences and clinical diagnostics sectors.